GH1 and urolithiasis: A greater percentage of acromegalic patients (78% vs. 50%) required re-procedures due to recurrent urolithiasis—even ones with already introduced pharmacological treatment (however, they were not optimally guided) which proves the persistent, negative effect of GH and IGF-1 on tissues and metabolic pathways, and calcium/phosphate metabolism.